Results 231 to 240 of about 34,279 (294)

Early‐life Giardia infection and behavioural dysregulation in two dogs: A case‐based exploration of the gut microbiome–brain axis

open access: yesVeterinary Record Case Reports, Volume 14, Issue 2, May 2026.
Abstract This case report describes two dogs exhibiting severe behavioural problems, both diagnosed with early‐life giardiasis and raised in environments lacking adequate maternal care and socialisation. Both dogs experienced chronic gastrointestinal and dermatological issues, as well as prolonged early‐life stress, which likely contributed to ...
Daniëlle Hartman   +3 more
wiley   +1 more source

GOES‐R Series X‐Ray Sensor (XRS): 2. On‐Orbit Measurements and Calibrations

open access: yesJournal of Geophysical Research: Space Physics, Volume 131, Issue 5, May 2026.
Abstract An X‐Ray Sensor (XRS) has been onboard each of the National Oceanic and Atmospheric Administration (NOAA) Geostationary Operational Environmental Satellites (GOES) since 1975. XRS measures full‐disk soft X‐ray irradiance in two wavelength bands, 0.05–0.4 nm and 0.1–0.8 nm.
Janet L. Machol   +17 more
wiley   +1 more source

T Cell Immunosenescence in Inflammatory Skin Diseases: Pathogenesis and Therapeutic Targets

open access: yesAging Cell, Volume 25, Issue 5, May 2026.
Immunosenescent T cells promote inflammatory skin diseases such as psoriasis, atopic dermatitis, rosacea, and seborrheic dermatitis via hyperactive signaling networks and SASP secretion. Consequently, intercepting downstream SASP, inhibiting internal pathways, or utilizing senolytics represents promising therapeutic interventions.
Conghui Liu   +3 more
wiley   +1 more source

The Placebo Effect in Rare Disease Clinical Trials: Measurement, Impact, and Statistical Approaches for Patient‐as‐Own‐Control Designs

open access: yesClinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT A frequently cited concern regarding patient‐as‐own‐control trial designs in rare disease is the potential for placebo and related effects to inflate apparent treatment efficacy. Whether this concern is disqualifying or manageable has not been systematically evaluated.
Marshall L. Summar, Janet Woodcock
wiley   +1 more source

The faintest, extremely variable X-ray tidal disruption event from a supermassive black hole binary? [PDF]

open access: yesInnovation (Camb)
Huang M   +32 more
europepmc   +1 more source

Evaluation of a Therapeutic Drug Monitoring Strategy for Adalimumab in Psoriasis: A Prospective Pharmacokinetic‐Pharmacodynamic Study

open access: yesClinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Using a real‐world psoriasis cohort, we established the pharmacokinetic‐pharmacodynamic (PKPD) relationship for the biologic therapy adalimumab and evaluated the clinical utility and cost‐effectiveness of a proactive therapeutic drug monitoring (TDM) strategy.
Shan Pan   +38 more
wiley   +1 more source

2025 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus. [PDF]

open access: yesRheumatol Immunol Res
Zhao J   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy